PIK3CA and neoplasm: Circulating tumor DNA sequencing was performed on 195 patients enrolled in the PALOMA-3 study, comparing baseline and end-of-treatment analyses (20), demonstrating the emergence of driver mutations in PIK3CA and ESR1.